Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) granted new US patent
Published by Arron Aatkar, PhD

Cantargia has announced that the US Patent and Trademark Office has granted the patent related to its lead candidate, nadunolimab. The patent covers the use of nadunolimab as a potential medicine in combination with chemotherapy and/or immunotherapy. We note that the lead indication being targeted is pancreatic ductal adenocarcinoma in combination with chemotherapy; this will be protected by the new patent. The patent is valid until 2035, excluding any potential extensions.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.